- Home
- LQDA
LQDA
Liquidia Corporation
as 05-30-2025 10:38am EST
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.
| Founded: | 2004 | Country: | United States |
| Employees: | N/A | City: | MORRISVILLE |
| Market Cap: | 1.4B | IPO Year: | 2018 |
| Target Price: | $27.13 | AVG Volume (30 days): | 2.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.71 | EPS Growth: | N/A |
| 52 Week Low/High: | $8.26 - $19.41 | Next Earning Date: | 05-08-2025 |
| Revenue: | $14,144,000 | Revenue Growth: | -11.42% |
| Revenue Growth (this year): | 224.65% | Revenue Growth (next year): | 250.54% |
Stock Insider Trading Activity of Liquidia Corporation (LQDA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Adair Jason | LQDA | Chief Business Officer | Apr 28 '25 | Sell | $14.24 | 455 | $6,479.20 | 183,849 | |
| Saggar Rajeev | LQDA | Chief Medical Officer | Apr 21 '25 | Sell | $13.67 | 2,450 | $33,491.50 | 263,152 | |
| Moomaw Scott | LQDA | Chief Commercial Officer | Apr 14 '25 | Sell | $13.57 | 3,406 | $46,219.42 | 214,744 | |
| JEFFS ROGER | LQDA | Chief Executive Officer | Apr 14 '25 | Sell | $13.57 | 14,130 | $191,744.10 | 1,006,420 | |
| Kaseta Michael | LQDA | CFO and COO | Apr 14 '25 | Sell | $13.57 | 8,283 | $112,400.31 | 396,315 | |
| Saggar Rajeev | LQDA | Chief Medical Officer | Apr 14 '25 | Sell | $13.57 | 3,714 | $50,398.98 | 263,152 | |
| Schundler Russell | LQDA | General Counsel | Apr 14 '25 | Sell | $13.57 | 5,964 | $80,931.48 | 570,301 | |
| Adair Jason | LQDA | Chief Business Officer | Apr 11 '25 | Sell | $13.57 | 1,856 | $25,185.92 | 183,849 |
Latest Liquidia Corporation News
LQDA Breaking Stock News: Dive into LQDA Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Liquidia Corporation to Present at the 2025 Jefferies Global Healthcare Conference
MT Newswires
3 days ago
Jefferies Lifts Liquidia Technologies' Price Target to $31 From $27, Buy Rating Kept
Insider Monkey
6 days ago
FDA Approves Liquidia Corporation (LQDA)’s YUTREPIA Amid Patent Dispute
MT Newswires
7 days ago
Liquidia Receives FDA Approval on Yutrepia for Treatment of Pulmonary Hypertension
GlobeNewswire
7 days ago
U.S. FDA Approves Liquidia’s YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
Simply Wall St.
9 days ago
3 Growth Companies With Insider Ownership Up To 19%
MT Newswires
11 days ago
Oppenheimer Downgrades Liquidia to Underperform From Perform, Price Target is $13
MT Newswires
18 days ago
Liquidia Faces Patent Litigation Filed by United Therapeutics
Compare LQDA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LQDA Liquidia Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.